{"id":49593,"date":"2026-03-27T01:02:13","date_gmt":"2026-03-27T01:02:13","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/49593\/"},"modified":"2026-03-27T01:02:13","modified_gmt":"2026-03-27T01:02:13","slug":"novo-nordisk-a-s-awiqli-approved-in-the-us-the-first-and-only-once-weekly-basal-insulin-treatment-for-adults-with-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/49593\/","title":{"rendered":"Novo Nordisk A\/S: Awiqli\u00ae approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes"},"content":{"rendered":"

Awiqli\u00ae (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDAAwiqli\u00ae offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per weekNovo Nordisk expects to launch Awiqli\u00ae nationwide in the US in the second half of 2026.Bagsv\u00e6rd, Denmark, 27 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli\u00ae (insulin icodec-abae) injection 700 units\/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control (blood sugar) in adults living with type 2 diabetes. The approval offers the only once\u2011weekly basal insulin option, providing a new treatment solution that fits different patient routines and preferences for adults living with type 2 diabetes.<\/p>\n

The approval is based on results from the ONWARDS phase 3a programme in type-2-diabetes for once-weekly Awiqli\u00ae injection, which comprises four randomised, active-controlled, treat-to-target trials in approximately 2,680 adults with uncontrolled type 2 diabetes, used in combination with a mealtime insulin or in combination with common oral anti-diabetic agents and\/or GLP-1 receptor agonists. The clinical programme evaluated once-weekly Awiqli\u00ae vs daily basal insulin and demonstrated efficacy in the primary endpoint of HbA1c reduction across the ONWARDS pivotal clinical trial programme in adults with type 2 diabetes. Across ONWARDS trials, the safety profile of Awiqli\u00ae was overall consistent with the daily basal insulin class.<\/p>\n

“The Awiqli\u00ae approval reflects Novo Nordisk\u2019s ongoing efforts to advance healthcare innovation and strengthen support for people living with diabetes. As the first FDA-approved, once-weekly basal insulin for adults with type 2 diabetes, it offers an important new treatment option. At a time when parts of the industry are stepping back from insulin, we are reaffirming our commitment – continuing to invest in innovation, access, and supply for the millions of patients who rely on insulin every day,\u201d said Mike Doustdar, president and CEO of Novo Nordisk.<\/p>\n

Novo Nordisk expects to launch Awiqli\u00ae in the FlexTouch\u00ae device in the US in the second half of 2026. Awiqli\u00ae is now approved in the US, EU, and 13 additional countries, with market-specific indications for diabetes.<\/p>\n

About Awiqli\u00ae<\/p>\n

Get the latest news
\n

\n delivered to your inbox<\/p>\n

Sign up for The Manila Times newsletters<\/p>\n

By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service<\/a> and Privacy Policy<\/a>.<\/p>\n

Awiqli\u00ae (insulin icodec-abae) injection 700 units\/mL is a prescription medicine and is the first and only FDA-approved once-weekly basal insulin indicated as an adjunct to diet and exercise for adults with type 2 diabetes. Awiqli\u00ae is designed as an alternative to daily basal insulin, and its approval is supported by the ONWARDS clinical programme, which evaluated its efficacy and safety across diverse adult populations living with type 2 diabetes. Awiqli\u00ae is administered once weekly on the same day each week using the Awiqli\u00ae FlexTouch\u00ae device.<\/p>\n

About Novo Nordisk<\/p>\n

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,<\/a>Facebook<\/a>, Instagram<\/a>, X<\/a>, LinkedIn<\/a> andYouTube<\/a>.<\/p>\n

Publication of inside information pursuant to Market Abuse Regulation, Article 17.<\/p>\n

Contacts for further information<\/p>\n

Company announcement No 22 \/ 2026<\/p>\n

Attachment<\/p>\n

CA260327-Awiqli-FDA-approval<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"Awiqli\u00ae (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDAAwiqli\u00ae offers adults with type…\n","protected":false},"author":2,"featured_media":49594,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[11200,1128,27738,141,27734,27733,27737,15786,6916,1380,216,24640,5691,3845,272,27736,27735,1967,12336,27739,652,4512],"class_list":["post-49593","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-11200","tag-a-s","tag-adults","tag-and","tag-approved","tag-awiqli","tag-basal","tag-diabetes","tag-first","tag-for","tag-in","tag-insulin","tag-nordisk","tag-novo","tag-novo-nordisk","tag-once-weekly","tag-only","tag-the","tag-treatment","tag-type","tag-us","tag-with"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116298445108923613","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/49593","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=49593"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/49593\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/49594"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=49593"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=49593"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=49593"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}